ESG stands for ‘environmental, social and governance’ – without a doubt a global mega trend, and even more so in the post Covid-19 world.
During this webinar, we will look at how a strong ESG proposition can create value. In particular, we will illustrate the value creation process by providing a framework tailored to the pharma value chain to describe the various options.
Continue reading Webinar: How can ESG create value in the pharma industry?We are delighted to invite you to our virtual Global Indirect Tax Health Industry Convention “Succeeding through uncertainty” on Thursday 6 May 2021 from 2pm to 6pm CEST. We will discuss the latest hot topics in the pharma, healthcare and life science industry from an indirect tax perspective and beyond.
The incredible pace of change in indirect taxes in the pharma, healthcare and life sciences industry shows no sign of slowing down. Digital transformation, changes in supply chains due to the pandemic, Brexit and complex developments in EU legislation are just some of the factors that are currently having a major impact on this industry and affecting almost every aspect of our business lives.
Dear pharma & life sciences colleagues,
As a tax/regulatory specialist within a pharmaceutical & life sciences company, you face complex sector-specific challenges each and every day.
You have to do more with fewer resources and find efficient and pragmatic solutions in line with rapidly changing local legislation.
Continue reading PwC Pharma & Life Sciences Webinar: Keep up to date with regulatory developmentsDear pharma & life sciences colleagues,
It was a pleasure to welcome you to our webinar: PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNA.
Attached below you can download the presentation.
Continue reading PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNAAs the COVID-19 situation develops, tax and regulatory specialists within the pharmaceutical & life sciences industry are increasingly facing complex challenges. Efficient and pragmatic solutions have to be realised, with fewer resources, in line with the changing local legislation.
The exchange of information is the best practice in this industry to support and inspire you in your daily business.
Continue reading PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNA – Thursday 28. May 2020, 10:30 CESTDear All
I would like to invite you to our next webinar “PwC webinar – “Sourcing and manufacturing without side effects!” which will be held on 31 March 2020 from 3:00 pm to 4:00 pm and on 1 April 2020 from 9.00 am to 10.00 am.
We will also include some ITX Updates related on COVID-19.
Continue reading PwC webinar – “Sourcing and manufacturing without side effects!” / COVID-19 ITX UpdateDear All
I would like to invite you to our next webinar “Pharma & VAT Quick Fixes – Exploring the Right Formula which will be held on 8 November 2019 from 9:00am to 10:00am and from 3.00pm to 4.00pm.
Continue reading Webinar: Pharma & VAT Quick Fixes – Exploring the Right FormulaDear all,
Happy to invite you to have a look to our latest PwC Webinar on precision medicines and the respective hot topics in the VAT field for the US, Europe, Switzerland and Asia. Continue reading Webinar on indirect tax issues in Precision Medicine
I am pleased to invite you to our Webinar on Precision Medicine
and Accurate Indirect Tax
During this digital presentation our panel of experts will give you an overview of possible indirect tax implications within the pharma sector. This panel consists of many tax specialists of the pharmaceutical sector and PwC’s international indirect tax experts. Experts, who are dedicated to the pharmaceutical industry.
I will use my time slot to discuss the implications for Switzerland including which countries will be covered.
You will have the opportunity to exchange your experiences and views on the issue with other international leaders.
Learn the latest news at our next international webinar
“ITX Pharma & Life Sciences Virtual Round Table” related to the ECJ Boehringer Ingelheim case.
I am looking forward to sharing this event with you.
